Neurotrope 10-Q 14 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	7-May-15
Document Information [Line Items]
Entity Registrant Name	Neurotrope, Inc.
Entity Central Index Key	1513856
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Trading Symbol	NTRP
Entity Common Stock, Shares Outstanding		27,490,540
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash and cash equivalents	$5,477,133	$8,010,357
Prepaid expenses	56,965	97,073
TOTAL CURRENT ASSETS	5,534,098	8,107,430
Fixed Assets, net of accumulated depreciation	55,225	53,618
TOTAL ASSETS	5,589,323	8,161,048
CURRENT LIABILITIES
Accounts payable	963,397	778,753
Accrued expenses	56,150	310,435
Accounts payable and accrued expenses - related party	0	200,000
TOTAL CURRENT LIABILITIES	1,019,547	1,289,188
Commitments and contingencies
Convertible redeemable preferred stock, Series A, $.0001 par value, 50,000,000 shares authorized; 18,757,394 and 21,363,000 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively. Liquidation preference of $18,757,394 plus dividends accruable at 8% per annum of $2,748,241 as of March 31, 2015 and Liquidation preference of $21,363,000 plus dividends accruable at 8% per annum of $2,687,835 at December 31, 2014	16,267,659	18,524,163
SHAREHOLDERS' DEFICIT
Common stock - 300,000,000 shares authorized, $.0001 par value; 26,876,040 issued and outstanding at March 31, 2015; 24,034,094 shares issued and outstanding at December 31, 2014	2,688	2,403
Additional paid-in capital	8,948,387	6,627,983
Accumulated deficit	-20,648,958	-18,282,689
TOTAL SHAREHOLDERS' DEFICIT	-11,697,883	-11,652,303
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$5,589,323	$8,161,048

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets [Parenthetical] (USD $)	Mar. 31, 2015	Dec. 31, 2014
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	26,876,040	24,034,094
Common stock, shares outstanding	26,876,040	24,034,094
Series A Convertible Redeemable Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	18,757,394	21,363,000
Preferred stock, shares outstanding	18,757,394	21,363,000
Preferred Stock, Liquidation Preference, Value (in dollars)	$18,757,394	$21,363,000
Dividends Payable Percentage (in percentage)	8.00%	8.00%
Dividends Payable (in dollars)	$2,748,241	$2,687,835

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
OPERATING EXPENSES:
Research and development - related party	$600,000	$651,859
Research and development	492,657	0
General and administrative - related party	27,000	27,000
General and administrative	1,186,358	845,147
Stock-based compensation - related party	43,336	66,763
Stock-based compensation	18,486	104,157
TOTAL OPERATING EXPENSES	2,367,837	1,694,926
OTHER INCOME:
Interest income	1,568	4,429
Net loss before income taxes	-2,366,269	-1,690,497
Provision for income taxes	0	0
Net loss	-2,366,269	-1,690,497
Preferred Stock dividends	-2,748,241	-1,471,050
Net loss attributable to common shareholders	($5,114,510)	($3,161,547)
PER SHARE DATA:
Basic and diluted loss per common share (in dollars per share)	($0.20)	($0.14)
Basic and diluted weighted average common shares outstanding (in shares)	25,016,000	21,881,000

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Changes in Shareholders' Deficit (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2014	($11,652,303)	$2,403	$6,627,983	($18,282,689)
Balance (in shares) at Dec. 31, 2014		24,034,094
Conversion of Series A preferred stock to common stock	2,256,504	261	2,256,243	0
Conversion of Series A preferred stock to common stock (in shares)		2,605,606
Stock based compensation	61,822	0	61,822	0
Exercise of common stock warrants	2,363	24	2,339
Exercise of common stock warrants (in shares)		236,340
Net loss	-2,366,269	0	0	-2,366,269
Balance at Mar. 31, 2015	($11,697,883)	$2,688	$8,948,387	($20,648,958)
Balance (in shares) at Mar. 31, 2015		26,876,040

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	($2,366,269)	($1,690,497)
Adjustments to reconcile net loss to net cash used by operating activities
Stock based compensation	61,822	170,920
Depreciation expense	1,436	0
Change in assets and liabilities
Increase in prepaid expenses	40,108	8,590
Decrease in accounts payable and accrued expenses - related party	-200,000	-136,631
Increase in accounts payable	184,644	15,522
Decrease in accrued expenses	-254,285	-10,129
Total adjustments	-166,275	48,272
Net Cash Used in Operating Activities	-2,532,544	-1,642,225
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	-3,043	0
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of common stock warrants	2,363	0
Net Cash Provided by Financing Activities	2,363	0
NET DECREASE IN CASH	-2,533,224	-1,642,225
CASH AT BEGINNING OF PERIOD	8,010,357	15,211,744
CASH AT END OF PERIOD	$5,477,133	$13,569,519
DISCLOSURE OF NON-CASH FINANCING ACTMTIES:
Conversion of Series A convertible redeemable preferred stock to common stock	2,256,504	132,378

Organization_and_Nature_of_Pla

Organization and Nature of Planned Business:	3 Months Ended
	Mar. 31, 2015
GENERAL ORGANIZATION AND BUSINESS [Abstract]
Nature of Operations [Text Block]	Note 1 – Organization and Nature of Planned Business:
	References in these notes to the unaudited condensed consolidated financial statements to “Neurotrope, Inc.,” “we,” “us,” “our Company” refer to Neurotrope, Inc. and its consolidated subsidiary Neurotrope Bioscience, Inc. (“Neurotrope BioScience”). Neurotrope BioScience was incorporated in Delaware on October 31, 2012. Neurotrope BioScience was formed to advance new therapeutic and diagnostic technologies in the field of neurodegenerative disease, primarily Alzheimer’s disease (“AD”). Neurotrope BioScience is collaborating with the Blanchette Rockefeller Neurosciences Institute (“BRNI”), a related party, in this process. The exclusive rights to the licensed technology transferred to the Company on February 28, 2013 (see Note 6).
	On August 23, 2013, a wholly-owned subsidiary of Neurotrope, Inc. (formerly “BlueFlash Communications, Inc.”), Neurotrope Acquisition, Inc., a corporation formed in the State of Nevada on August 15, 2013 merged (the “Reverse Merger”) with and into Neurotrope BioScience. Neurotrope BioScience was the surviving corporation in the Reverse Merger and became the Company’s wholly-owned subsidiary. All of the outstanding Neurotrope BioScience common stock was converted into shares of Neurotrope, Inc. common stock on a one-for-one basis.
	The transaction was accounted for as a reverse merger and recapitalization with Neurotrope BioScience as the acquirer for financial reporting purposes and Neurotrope, Inc. as the acquired company. Consequently, the assets and liabilities and the operations that are reflected in the historical financial statements are those of Neurotrope BioScience and are recorded at the historical cost basis of Neurotrope BioScience, and the consolidated financial statements after completion of the Reverse Merger include the assets and liabilities of Neurotrope BioScience and Neurotrope, Inc., and the historical operations of Neurotrope, Inc. and Neurotrope BioScience from the closing date.
	As a result of the Reverse Merger, Neurotrope, Inc. discontinued its pre-Reverse Merger business and acquired the business of Neurotrope BioScience, which it is continuing to operate through Neurotrope BioScience. The common stock of Neurotrope, Inc. is traded under the ticker symbol “NTRP.”
	Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) have been condensed or omitted. These consolidated financial statements should be read in conjunction with the Consolidated Financial Statements and Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2014.

Going_Concern

Going Concern:	3 Months Ended
	Mar. 31, 2015
Going Concern [Abstract]
Going Concern [Text Block]	Note 2 – Going Concern:
	The unaudited consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the consolidated financial statements, we have generated no revenues to-date, have incurred substantial losses during the Company’s development stage and have substantial contractual commitments pursuant to various agreements to which we are a party.
	Our ability to continue existence is dependent upon our continuing efforts to obtain additional financing to carry out our business plan during the development stage. We intend to fund our operations through equity and/or debt financing arrangements and any revenues generated in the future. However, there can be no assurance that these arrangements, if any, will be sufficient to fund our ongoing capital expenditures, working capital, and other cash requirements. The outcome of these matters cannot be predicted at this time.
	There can be no assurance that any additional financings will be available to us on satisfactory terms and conditions, if at all. These conditions raise substantial doubt as to our ability to continue as a going concern.
	The consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should we be unable to continue as a going concern.

Summary_of_Significant_Account

Summary of Significant Accounting Policies:	3 Months Ended
	Mar. 31, 2015
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract]
Significant Accounting Policies [Text Block]	Note 3 - Summary of Significant Accounting Policies:
	Use of Estimates:
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Reclassifications:
	Certain reclassifications have been made to the 2014 financial statements to conform to the consolidated 2015 financial statement presentation. These reclassifications had no effect on net loss or cash flows as previously reported.
	Cash and Cash Equivalents:
	The Company considers all highly liquid temporary cash investments with an original maturity of three months or less when purchased to be cash equivalents. At March 31, 2015, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation.
	Property and Equipment:
	Property and equipment is capitalized and depreciated on a straight line basis over the useful life of the asset, which is deemed to be between three and ten years. Property and equipment consist of the following:
		March 31,		December 31,
		2015		2014
	Property and equipment	$	57,987	$	54,943
	Accumulated depreciation	$	-2,762	$	-1,325
	Property and equipment, net	$	55,225	$	53,618
	Depreciation expense for the three months ended March 31, 2015 and 2014 was $1,436 and $0, respectively.
	Research and Development Costs:
	All research and development costs, including costs to maintain or expand the Company’s patent portfolio that do not meet the criteria for capitalization are expensed when incurred. FASB ASC Topic 730 requires companies involved in research and development activities to capitalize non-refundable advance payments for such services pursuant to contractual arrangements because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at March 31, 2015 and December 31, 2014.
	Income Taxes:
	Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes. Deferred taxes are recognized for differences between the bases of assets and liabilities for financial statement and income tax purposes and the tax effects of net operating loss and other carryforwards. The deferred tax assets and liabilities represent the future tax consequences of those differences and carryforwards, which will either be taxable or deductible when the related assets, liabilities or carryforwards are recovered or settled. Deferred tax assets are reduced by a valuation allowance when, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized.
	The Company applies the provisions of FASB ASC 740-10, Accounting for Uncertain Tax Positions, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The standard also provides guidance on de-recognition, classification, interest and penalties, and accounting in interim periods, disclosure and transitions.
	The Company has concluded that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions is from October 31, 2012 (inception) through March 31, 2015.
	In the event the Company was to receive an assessment for interest and/or penalties, it will be classified in the financial statements as selling, general and administrative expense when assessed.
	Risks and Uncertainties:
	The Company operates in an industry that is subject to rapid technological change, intense competition and significant government regulation. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risk. Such factors include, but are not necessarily limited to, the results of clinical testing and trial activities, the ability to obtain regulatory approval, the ability to obtain favorable licensing, manufacturing or other agreements for its product candidates and the ability to raise capital to achieve strategic objectives.
	Stock Compensation:
	The Company accounts for stock-based awards to employees in accordance with applicable accounting principles, which requires compensation expense related to share-based transactions, including employee stock options, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. For all employee stock options, we recognize expense over the employee’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the expected stock price volatility, expected term, and forfeiture rate. Any changes in these highly subjective assumptions significantly impact stock-based compensation expense.
	Options awarded to purchase shares of common stock issued to non-employees in exchange for services are accounted for as variable awards in accordance with applicable accounting principles. Such options are valued using the Black-Scholes option pricing model.

Contractual_Commitments

Contractual Commitments:	3 Months Ended
	Mar. 31, 2015
Contractual Commitments [Abstract]
Contractual Commitments [Text Block]	Note 4 – Contractual Commitments:
	Effective as of July 16, 2014, the Company’s former President’s employment as Chief Executive Officer and President of Neurotrope BioScience and the Company was terminated. In connection with the termination, effective as of July 16, 2014, Neurotrope BioScience and its former President entered into a separation agreement and general release on October 9, 2014 (the “Separation Agreement”).
	The Separation Agreement states that Neurotrope BioScience will pay or provide to the former President the following: (a) $2,684 within three days of the execution of the Separation Agreement by him, representing reimbursement of business expenses; (b) a lump sum equal to the total gross amount of $233,000; (c) a gross amount of $25,478 for his accrued, unused vacation; (d) reimbursement for the cost of continuing his current health care insurance in the same amount as the net reimbursement amounts paid to him on a monthly basis immediately prior to July 16, 2014 ($2,974 per month) until the earlier of the date on which he becomes eligible for medical insurance coverage with a new employer or July 16, 2015; (e) director’s and officer’s insurance coverage covering his actions while a director and/or officer of Neurotrope BioScience until July 16, 2020; and (f) $17,000 for reimbursement of his attorneys fees. In addition, the parties agreed that his ownership of any common shares of the company is not affected by the Separation Agreement and that any equity awards he received pursuant to the 2013 Equity Incentive Plan will be governed exclusively by the terms of such plan. Approximately $282,000 was paid to him pursuant to the Separation Agreement in 2014.
	Effective February 28, 2013, the Company executed an agreement with Ramat Consulting Corp. (“Ramat”), a related party to the Company’s current President and CEO Charles S. Ramat, for consulting services, including business development and marketing consulting, for a five-year period, subject to annual renewals thereafter. The Ramat agreement was amended on February 2, 2015 to add Mr. Ramat’s duties as the Company’s President and CEO. Ramat's annual fee is $50,000, payable in monthly installments of $4,167, plus pre-approved travel and other reimbursable expenses. Ramat was issued a non-qualified option, with a term of ten years, to purchase 300,000 shares of common stock of the Company at an exercise price of $1.00 per share. The option vested with respect to 20% of the shares as of February 28, 2013, and the balance vest on a daily basis over the four-year period beginning on February 28, 2013. Vested options will terminate, to the extent not previously exercised, upon the occurrence of the first of the following events: (a) ten years from the date of grant; (b) the expiration of one year from the date of death or the termination of optionee as a service provider by reason of disability; or (c) the expiration of twelve months from the date of termination of optionee’s service as a service provider for any reason whatsoever other than termination of service for death or disability. An entity related to Ramat purchased 1,000,000 shares of the Company’s Series A Preferred Stock on the effective date of the consulting agreement described in this paragraph. (See Note 12 – “Subsequent Events” for additional information regarding Mr. Ramat’s compensation arrangement).
	On October 1, 2013, the Company executed a four-year employment agreement, effective October 1, 2013, with Robert Weinstein, its current Executive Vice President, Chief Financial Officer, Treasurer and Secretary. This agreement provides for an annual salary of $240,000, which increased to an annual salary of $275,000 beginning January 1, 2015 plus a bonus arrangement of 50% of base salary for all subsequent years. On October 1, 2013, the Company’s Board of Directors (the “Board”) granted an incentive stock option to Mr. Weinstein under the Company’s 2013 Equity Incentive Plan (the “2013 Plan”) to purchase 650,000 shares of the Company’s common stock, with a term of ten years, exercisable at $1.00 per share. These options vest 25% per year over four years, with accelerated vesting of 25% upon a termination without cause or for good reason.
	On January 16, 2014, the Company executed a four-year employment letter with Neurotrope BioScience’s Vice President – Commercial Operations. This employment letter provides for an annual salary of $210,000 which shall increase at the discretion of the Company’s Compensation Committee. In addition, the employment letter provides for a discretionary bonus of up to 35% of base salary for all years. On January 23, 2014, the Board granted an incentive stock option to its Vice President – Commercial Operations under the 2013 Plan to purchase 100,000 shares of the Company’s common stock, with a term of ten years, exercisable at $1.76 per share. These options vest 20% per year over five years. Vested options will terminate, to the extent not previously exercised, upon the occurrence of the first of the following events: (a) ten years from the date of grant; or (b) the expiration of one year from the date of death, disability or the termination of employment.
	On January 22, 2014, the Company executed a four-year employment agreement with Neurotrope BioScience’s former Vice President and Chief Medical Officer. This agreement provided for an annual salary of $210,000. On January 23, 2014, the Board granted an incentive stock option to its former Vice President and Chief Medical Officer under the 2013 Plan to purchase 125,000 shares of the Company’s common stock, with a term of ten years, exercisable at $1.76 per share. On October 31, 2014, the Company terminated Neurotrope BioScience’s former Vice President and Chief Medical Officer without cause. Upon termination without cause and conditioned upon the execution of a release, he received severance and accelerated vesting of a portion of his incentive stock option to purchase 31,250 shares of the Company’s common stock. These options have lapsed. Approximately $217,000 was accrued for this severance arrangement in 2014 and paid in February 2015.
	On June 1, 2014, the Company executed a four-year employment letter, with Neurotrope BioScience’s Executive Director – Pharmacology. This employment letter provides for an annual salary of $180,000 which shall increase at the discretion of the Company’s Compensation Committee. In addition, the employment letter provides for a discretionary bonus of up to 25% of base salary for all years. On July 16, 2014, the Board granted an incentive stock option to the Executive Director for the purchase of 50,000 shares of the Company’s common stock (see Note 10 – “Stock Options” for details).
	On July 16, 2014, the Board appointed Charles S. Ramat and Paul E. Freiman to serve as Co-Chief Executive Officers, on an interim basis, of the Company and of Neurotrope BioScience. Mr. Freiman has served on the Board since October 18, 2013, and was appointed Co-Chairman of the Board on June 13, 2014. Mr. Ramat was elected to the Board on June 13, 2014 and was immediately appointed Co-Chairman of the Board.
	In consideration of the services to be provided by Mr. Freiman and Mr. Ramat to the Company as Co-Chief Executive Officers, the Company agreed to pay each of them consulting fees in the amount of $20,000 per month for a term not to exceed six months, which fees would be reduced upon the employment of a permanent Chief Executive Officer to $10,000 per month for two months to aid in the transition of responsibilities to the new Chief Executive Officer. In addition, on July 23, 2014, Messrs. Freiman and Ramat were each granted non-qualified options to purchase 400,000 shares of the Company’s common stock for their roles as directors, Co-Chairmen of the Board and Co-Chief Executive Officers. Options to purchase 200,000 shares have an exercise price of $1.11 per share, or 110% of the Company’s last trading price on July 23, 2014 and were fully vested upon grant. Options to purchase the remaining 200,000 shares have an exercise price of $2.22 per share based upon two times the exercise price of $1.11 per share and vest on a daily basis up to 25% per year through July 23, 2018. See below regarding further changes to Messrs. Ramat and Freiman’s roles with the Company.
	On September 4, 2014, the Company entered into a long-term lease for 4,000 square feet of office space in Newark, New Jersey. The lease commenced September 1, 2014 and expires December 1, 2017 and has two (2) one-year renewal options. The base rent is payable, commencing December 1, 2014, at an annual rate of $88,000 with no increases during the lease term and renewal terms. In addition, commencing September 1, 2014, the Company is obligated to pay its share of common area charges. The Company is amortizing the total base rent due over 39 months.
	On September 12, 2014, the Board elected Mr. Ramat to be the Company’s President and Chief Executive Officer and Mr. Freiman to be the Company’s Chairman of the Board. In consideration of the services that Mr. Ramat will provide to the Company as President and CEO, the Company agreed to pay Mr. Ramat a consulting fee of $400,000 per year with a bonus opportunity of up to 50% of his consulting fee after one (1) year of service, which arrangement could have been terminated by either party on 60 days’ notice, but has been amended to 180 days’ notice (See Note 12 – “Subsequent Events”). Mr. Ramat’s consulting fee replaces the $20,000 per month consulting fee of July 16, 2014. Mr. Freiman’s compensation remains at $20,000 per month as Chairman of the Board. In addition to his salary for services as President and Chief Executive Officer of the Company, Mr. Ramat will continue to be paid the consulting fees under a Consulting Agreement with the Company pursuant to which he receives $50,000 per year.
	In addition, on September 12, 2014, Messrs. Ramat and Freiman were granted non-qualified options to purchase 250,000 and 50,000 shares of the Company’s common stock, respectively, which have an exercise price of $0.60 per share, are fully vested upon grant, and have a ten-year life.
	As of November 1, 2014, Neurotrope BioScience entered into an employment agreement for one (1) year with provisions for automatic renewals, with its Executive Vice President, Development and Chief Medical Officer. This agreement provides for an annual salary of $325,000 which shall increase at the discretion of the Company’s President. In addition, the employment agreement provides for a signing bonus of $102,083 in total, payable $8,507 monthly (if employed during the applicable payment cycle) and a discretionary bonus of up to 50% of base salary. In connection with his employment and as of his date of hire, the Company’s Compensation Committee authorized a grant of a non-qualified stock option to Neurotrope BioScience’s Executive Vice President and Chief Medical Officer under the 2013 Plan to purchase 250,000 shares of the Company’s common stock, with a term of ten years, exercisable at $0.71 per share. These options vest 20% per year over five years commencing November 1, 2015.

Collaborative_Agreements

Collaborative Agreements:	3 Months Ended
	Mar. 31, 2015
Collaborative Agreements [Abstract]
Collaborative Agreements [Text Block]	Note 5 – Collaborative Agreements:
	On May 12, 2014, the Company entered into a license agreement (the “Stanford Agreement”) with The Board of Trustees of The Leland Stanford Junior University (“Stanford”), pursuant to which Stanford has granted to the Company a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of bryostatin structural derivatives, known as “bryologs,” for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury, for the life of the licensed patents.
	Pursuant to the Stanford Agreement, in 2014, the Company paid Stanford a total of $60,850, of which $48,564 was expensed by the Company in 2014. The Company is also obligated to pay Stanford: (a) a $10,000 annual license maintenance fee; (b) milestone payments in the aggregate amount of up to $3,700,000 upon the achievement of certain product development events commencing upon the filing of the first IND application through approval of an applicable product; and (c) low single-digit royalties on net sales of licensed products.
	Each party has the right to terminate the Stanford Agreement for an uncured material breach of the other party. Additionally, the Company may terminate the Stanford Agreement at any time upon 60 days’ written notice to Stanford.
	On May 15, 2014, the Company entered into an agreement with a contract research organization (“CRO”) to conduct a clinical trial relating to AD. The Company has agreed to pay fees to the CRO totaling $715,159, based upon signing of the agreement and the CRO achieving certain clinical trial milestones, plus reasonable out-of-pocket expenses. On November 19, 2014, the CRO agreement was amended, requiring the Company to pay a reduced amount totaling $657,238 plus third party pass through expenses. The Company has incurred a total of $687,112 in fees, $377,225 and $417,877 of which are included in the balance sheet as payables as of March 31, 2015 and December 31, 2014, respectively.
	On July 14, 2014, Neurotrope BioScience entered into an Exclusive License Agreement (the “Mount Sinai Agreement”) with Icahn School of Medicine at Mount Sinai (“Mount Sinai”). Pursuant to the Mount Sinai Agreement, Mount Sinai granted Neurotrope BioScience a revenue-bearing, world-wide right and (a) exclusive license, with the right to grant sublicenses (on certain conditions), under Mount Sinai’s interest in certain joint patents held by the Company and Mount Sinai (the “Joint Patents”) as well as in certain results and data (the “Data Package”) and (b) non-exclusive license, with the right to grant sublicenses on certain conditions, to certain technical information, both relating to the diagnostic, prophylactic or therapeutic use for treating diseases or disorders in humans relying on activation of PKC epsilon, which includes Niemann-Pick C Disease (the “Mount Sinai Field of Use”). The Mount Sinai Agreement allows Neurotrope BioScience to research, discover, develop, make, have made, use, have used, import, lease, sell, have sold and offer certain products, processes or methods that are covered by valid claims of Mount Sinai’s interest in the Joint Patents or an Orphan Drug Designation Application covering the Data Package (“Mount Sinai Licensed Product(s)”) in the Mount Sinai Field of Use.
	Pursuant to the Mount Sinai Agreement, Neurotrope BioScience is obligated to pay a $25,000 license initiation fee to Mount Sinai. Neurotrope BioScience is also obligated to pay Mount Sinai (a) a $10,000 annual license maintenance fee until minimum royalty payments are due, (b) milestone payments in the aggregate amount of up to $3,500,000 upon the achievement of certain product development events relating to the approval of a Mount Sinai Licensed Product in the United States and other jurisdictions, (c) low single-digit royalties on net sales of the Mount Sinai Licensed Products, and (d) a portion of sublicense fees ranging from a significant double-digit percentage based on sublicensing before completion of in vivo proof-of-concept experiments to a mid-single digit percentage after product approval. In 2014, the Company paid Mount Sinai $25,000, which represents the license initiation fee described above. Of this $25,000, the Company expensed $11,458 in 2014. Also in 2014, the Company accrued $12,000 as an expense to Mount Sinai for certain consulting services that the Company paid in the fiscal quarter ended March 31, 2015.
	Each party has the right to terminate the Mount Sinai Agreement for an uncured material breach of the other party. Additionally, Neurotrope BioScience may terminate the Mount Sinai Agreement at any time upon 60 days’ written notice to Mount Sinai. Further, upon termination, Neurotrope BioScience may continue to sell any and all Mount Sinai Licensed Products, provided that Neurotrope BioScience will pay Mount Sinai a reduced royalty for Mount Sinai Licensed Products that are indicated as therapeutics or diagnostics for Niemann Pick disease which are sold following the termination of the Mount Sinai Agreement.
	The term of the Mount Sinai Agreement began upon signing and will expire with respect to each Mount Sinai Licensed Product on a Mount Sinai Licensed Product-by-Mount Sinai Licensed Product basis and country-by-country basis, from first commercial sale until the later of: (a) expiration of the last to expire Joint Patent Rights covering such Mount Sinai Licensed Product in such country; (b) expiration of any market exclusivity period granted by a regulatory agency with respect to such Mount Sinai Licensed Product in such country; or (c) ten years after the first commercial sale of such Mount Sinai Licensed Product in such country.
	On March 30, 2015, Neurotrope Bioscience signed a letter of intent with Worldwide Clinical Trials (“WCT”) to commence pre-patient enrollment activities for the conduct of a Phase 2b clinical trial of the Company’s compound, bryostatin-1, for the treatment of Alzheimer’s disease. The letter of intent outlines the scope of the services that WCT will provide to the Company. The Company will pay WCT approximately $300,000 for the services and related third-party costs pursuant to the terms of the letter of intent.

Related_Party_Transactions_and

Related Party Transactions and Licensing / Research Agreements:	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 6 – Related Party Transactions and Licensing / Research Agreements:
	Two directors of the Company, James Gottlieb and William Singer, are also directors of BRNI. Mr. Singer is the president of BRNI. BRNI is a stockholder of a corporation, Neuroscience Research Ventures, Inc. (“NRVI”), which owned 33.6% of the Company's outstanding common stock as of March 31, 2015.
	Effective October 31, 2012, Neurotrope BioScience executed a Technology License and Services Agreement with BRNI, a related party, and NRV II, LLC, another affiliate of BRNI. As of February 4, 2015, the parties entered into an Amended and Restated Technology License and Services Agreement (the “BRNI License Agreement”). The BRNI License Agreement further amended and restated that certain Technology License and Services Agreement executed as of October 31, 2012, which was previously amended by Amendment No. 1 to the Technology License and Services Agreement as of August 21, 2013. Under the terms of the BRNI License Agreement, BRNI provides research services and granted Neurotrope BioScience the exclusive and nontransferable license right to certain patent and intellectual property which became effective upon the Neurotrope BioScience’s completion of a Series A Preferred Stock financing generating net proceeds to Neurotrope BioScience of at least $8,000,000 on February 28, 2013. The BRNI License Agreement terminates on the later of the date (a) the last of the licensed patent expires, is abandoned, or is declared unenforceable or invalid or (b) the last of the intellectual property enters the public domain.
	After the initial Series A Preferred Stock financing, the BRNI License Agreement requires Neurotrope BioScience to enter into scope of work agreements with BRNI as the preferred service provider, for any research and development services or other related scientific assistance and support services. Neurotrope BioScience is not permitted to engage any other person other than BRNI to perform research or development services or other related scientific assistance without prior written consent of BRNI, except under certain circumstances. BRNI and Neurotrope may agree to have a third party provide services identical or similar to such services to Neurotrope in the case where BRNI is demonstrably unable to do so or such third party is demonstrably in a superior position to do so.
	In addition, the BRNI License Agreement requires the Company to pay BRNI a “Fixed Research Fee,” commencing the date that the Company completes a Series B Preferred Stock financing resulting in net proceeds of at least $25,000,000 (the “Series B Financing”). The fixed research fee is (a) a pro-rata amount of $1,000,000 in the year the Company completes such financing (b) $1,000,000 per year for five calendar years subsequent to such financing and (c) an annual fixed research fee in an amount to be negotiated and agreed upon no later than 90 days prior to the end of the fifth calendar year following the completion of such financing to be paid with respect to each remaining calendar year during the term of the BRNI License Agreement. The Company has not yet completed this Series B Financing (see Note 9) and, accordingly, no such fees are due.
	The BRNI License Agreement also requires the payment of royalties ranging between 2% and 5% of the Company’s revenues generated from the licensed patents and other intellectual property, dependent upon the percentage ownership that NRVI holds in the Company. Under the BRNI License Agreement, the Company is required to prepay royalty fees at a rate of 5% of all investor funds raised in the Series A or Series B Preferred Stock financings or any subsequent rounds of financing prior to a public offering, less commissions.
	Pursuant to the BRNI License Agreement, on February 4, 2015, Neurotrope BioScience and BRNI entered into a new Statement of Work and Account Satisfaction Agreement, or the February 2015 SOW. The February 2015 SOW is effective as of October 1, 2014 and continues until September 30, 2015.
	Pursuant to the February 2015 SOW, Neurotrope BioScience agreed to pay BRNI $2,400,000 in service fees and other amounts payable at a rate of $200,000 per month for each month from October 1, 2014 through September 30, 2015. The parties agreed that the first $600,000 of payments satisfy certain outstanding amounts owed to BRNI. Of this $600,000, $400,000 was paid in 2014, and the remaining $200,000 was paid in 2015. Neurotrope BioScience also agreed to pay BRNI $20,000 in quarterly payments during the twelve months from the date of the SOW in exchange for advising and consulting services by BRNI’s chief scientist regarding Neurotrope BioScience’s contract with the Icahn School of Medicine at Mt. Sinai Hospital for the use of bryostatin in the treatment of Niemann Pick disease.
	In consideration for the February 2015 SOW, BRNI agrees to (a) use commercially reasonable efforts to enroll at least four (4) additional compassionate use or expanded access patients, in trials of BRNI’s Alzheimer’s therapeutic drug platform during the term of the SOW, (b) perform certain services requested by Neurotrope BioScience for the further development of BRNI’s Alzheimer’s therapeutic drug platform, (c) perform certain services for the further development of BRNI’s Alzheimer’s diagnostic test, (d) to the extent permitted by applicable law, transfer all of its rights and regulatory obligations, except for those relating to the compassionate use expanded access trials, associated with BRNI’s Investigative New Drug Application (IND) 71,276 to Neurotrope BioScience, (e) conduct initial research on the application of its PKC epsilon platform to treat Fragile X disease, (f) conduct initial research on polyunsaturated fatty acid derivatives for the purpose of developing a commercially usable PKC epsilon activator, and (g) provide assistance, advice and other similar services to Neurotrope BioScience regarding Neurotrope BioScience’s analysis of bryologs pursuant to Neurotrope BioScience’s agreement with Stanford University, for the purpose of developing a commercially usable PKC epsilon activator. Furthermore, BRNI agreed to transfer a certain amount of bryostatin drug substance and bryostatin kits containing drug substance for non-human use to a third-party for storage and handling for Neurotrope BioScience’s pre-clinical and clinical use, which was completed on March 10, 2015.
	In order for BRNI to perform certain of the services described in (c) above, Neurotrope BioScience agrees, at a reasonable time, to reimburse a third party for services BRNI received from such third party in the amount of $150,000 in connection with BRNI’s former diagnostic trial program with such third party. Also, under certain conditions, Neurotrope BioScience has agreed to enter into an agreement with a specified research institution for the analysis of tissue samples and autopsy results for a validation trial as part of the development process for the diagnostic test. If Neurotrope BioScience does not proceed with a certain portion of such agreement by June 30, 2015, then the rights to the diagnostic test will revert to BRNI and Neurotrope BioScience will no longer be licensed thereto.
	For the three months ended March 31, 2015, Neurotrope BioScience incurred $600,000 in expenses relating to the February 2015 SOW.
	See Note 4 for additional related party transactions.

Income_Taxes

Income Taxes:	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 7– Income Taxes:
	The Company incurred a net operating loss for income tax purposes of $15,990,210 for the period from October 31, 2012 (inception) through March 31, 2015. Income tax effects of share-based payments are recognized in the financial statements for those awards that will normally result in tax deductions under existing tax law. Under current U.S. federal tax law, the Company would receive a compensation expense deduction related to non-qualified stock options only when those options are exercised. Accordingly, the financial statement recognition of compensation cost for non-qualified stock options creates a deductible temporary difference which results in a deferred tax asset of approximately $250,000 as of March 31, 2015. The Company does not recognize a tax benefit for compensation expense related to incentive stock options (ISOs) unless the underlying shares are disposed of in a disqualifying disposition. Accordingly, compensation expense related to ISOs is treated as a permanent difference for income tax purposes. These deferred tax assets are reduced to zero by an offsetting valuation allowance. As a result, there is no provision for income taxes.

Common_Stock

Common Stock:	3 Months Ended
	Mar. 31, 2015
STOCKHOLDERS' EQUITY [Abstract]
Stockholders Equity Note Disclosure [Text Block]	Note 8 – Common Stock:
	During the quarter ended March 31, 2015, 19 holders of 2,605,606 total shares of Preferred Stock converted that Preferred Stock into 2,605,606 shares of Neurotrope’s common stock and seven holders of 236,340 warrants exercisable at $0.01 per share of common stock exercised their warrants into 236,340 shares of Neurotrope’s common stock. During the year ended December 31, 2014, ten holders of 1,637,000 total shares of Preferred Stock converted that Preferred Stock into 1,637,000 shares of Neurotrope’s common stock and five holders of 613,228 warrants exercisable at $0.01 per share of common stock exercised their warrants into 613,228 shares of Neurotrope’s common stock.

Preferred_Stock

Preferred Stock:	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Preferred Stock [Text Block]	Note 9 – Preferred Stock:
	As of September 2, 2014, the Company and the holders of a majority of the Company’s Series A Preferred Stock entered into an amendment (the “Amendment”) to the Preferred Stockholders Agreement, dated as of August 23, 2013 (the “Preferred Stockholder Agreement”). Under the terms of the Amendment, the parties removed provisions relating to the right of first refusal and certain prohibitions relating to transfers, which were set forth in the Preferred Stockholder Agreement. In addition, the parties made other technical changes to the terms of the Preferred Stockholder Agreement.

Stock_Options

Stock Options:	3 Months Ended
	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Stock Option Note Disclosure [Text Block]	Note 10 – Stock Options:
	Our Board of Directors adopted, and our stockholders approved, the 2013 Plan, which provides for the issuance of incentive awards of up to 7,000,000 shares of the Company’s common stock to officers, key employees, consultants and directors. Upon the closing of the Reverse Merger, options to purchase an aggregate of 5,154,404 shares of the Company’s common stock were issued. Of these options: (a) 3,500,000 options were issued to founding stockholders and 54,404 were granted to a consultant, each with a term of ten years, exercisable at $1.75 per common share, 100% of these options vested on the date of grant; (b) 1,050,000 options were issued to four directors (or their affiliates) and 250,000 to a consultant with a term of ten years, exercisable at $1.00 per common share, which vest 20% per year for each of five years after the date of grant; and, (c) 300,000 options were granted to a consultant with a term of ten years, exercisable at $1.00 per common share which vested 20% on the date of grant and vest 20% per year over the next four years. These options were issued in conversion of options issued by Neurotrope BioScience on February 28, 2013.
	On January 23, 2014, the Company issued, under the 2013 Plan, 300,000 options to three employees, each with a term of ten years, exercisable at $1.76 per common share. 125,000 of these options vest 25% per year, with accelerated vesting of 25% upon a termination without cause or for good reason, with the remaining 175,000 vesting 20% per year. On March 21, 2014, the Company issued, under the 2013 Plan, 30,000 options to one employee with a term of ten years, exercisable at $2.30 per common share and vests 20% per year commencing on March 31, 2015.
	On July 16, 2014, the Company issued incentive stock options to purchase 50,000 shares of common stock under the 2013 Plan to one employee with a term of ten years, exercisable at $1.24 per common share which vest 20% per year commencing July 16, 2015.
	On July 23, 2014, the Company’s Board approved increasing the total shares available under the 2013 Plan by 3,000,000 to 10,000,000. The 3,000,000 additional shares will be issuable as non-qualified stock options, unless shareholder approval is received.
	Also, on July 23, 2014, the Board granted non-qualified stock options to three directors, each in the amount of 100,000 shares of common stock; 50,000 of which have an exercise price equal to $1.11, which vested on the date of the grant hereof; and 50,000 of which have an exercise price equal to two times the value of the exercise price of the first 50,000 options, or $2.22 which vest daily over four (4) years (assuming continued service on behalf of the Company), up to 25% per year, until the grant is fully vested on July 23, 2018.
	On September 12, 2014, the Board granted the Company’s Chief Executive Officer and Chairman non-qualified options to purchase 250,000 and 50,000 shares of the Company’s common stock, respectively, which have an exercise price of $0.60 per common share, are fully vested upon grant and have a term of ten years. Also, the Board granted 300,000 non-qualified stock options to a newly appointed director with a term of ten years, exercisable at $0.60 per common share and vest daily over five years commencing September 12, 2014. The Company also granted incentive stock options to purchase 20,000 shares of the Company’s common stock to one employee with a term of ten years, exercisable at $0.60 per common share and vests 20% per year commencing September 12, 2015.
	A summary of the Company’s stock option activity for the three months ending March 31, 2015 is as follows:
		Options	Weighted-Average
		Outstanding	Exercise Price
	Outstanding at January 1, 2015	7,769,202	$	1.4
	Options granted	70,000	$	1.17
	Options forfeited	-51,250	$	-1.52
	Options exercised	0		0
	Outstanding at March 31, 2015	7,787,952	$	1.39
	Options exercisable March 31, 2015	4,738,294	$	1.49
	The weighted-average remaining contractual term of options exercisable and outstanding at March 31, 2015 was approximately 8.6 and 8.7 years, respectively.
	The Company used the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method.
	The fair value of stock options issued for the three months ended March 31, 2015 was estimated at the grant date using the following weighted average assumptions: Dividend yield 0%; Volatility 91.85%; Risk-free interest rate 1.98%; weighted average grant date fair value of $1.02 per common share. There is no current allowance for forfeitures.
	The total stock option-based compensation recorded as operating expense was $61,822 and $170,920 for the three months ended March 31, 2015 and 2014, respectively. All of the stock option-based compensation expense was classified as stock based compensation expense.

Common_and_Preferred_Stock_Res

Common and Preferred Stock Reserved for Future Issuances:	3 Months Ended
	Mar. 31, 2015
Common And Preferred Stock Reserved For Future Issuances [Abstract]
Common And Preferred Stock Reserved For Future Issuances [Text Block]	Note 11 – Common and Preferred Stock Reserved for Future Issuances:
	Common stock reserved for future issuances consisted of the following at March 31, 2015:
		Common Stock
		Reserved
	Common stock warrants outstanding		1,375,432
	Common stock options outstanding		7,787,952
	Conversion of Series A Preferred Stock		18,757,394
	Total		27,920,778
	On February 9, 2015, the holders of placement agent warrants to purchase an aggregate of 1,325,000 shares of our Series A Preferred Stock entered into Conversion Agreements with us pursuant to which such holders’ placement agent warrants to purchase Series A Preferred Stock were converted, for no additional consideration, into common stock purchase warrants to purchase an aggregate of 1,325,000 shares of our common stock.

Subsequent_Events

Subsequent Events:	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 12 – Subsequent Events:
	From April 1 through May 7, 2015, private placement investors converted a total of 614,500 shares of the Company’s Series A Preferred Stock (issued in 2013) into 614,500 shares of the Company’s common stock.
	On April 10, 2015, the Board of Directors (the “Board”) of Neurotrope, Inc. approved an amendment to its compensation arrangement with Mr. Charles Ramat relating to his services as President and Chief Executive Officer of Neurotrope. The arrangement now provides that Mr. Ramat’s services as President and Chief Executive Officer of Neurotrope may be terminated by either the Company or Mr. Ramat on 180 days’ notice, instead of 60 days’ notice.
	On the same date, the Board also agreed to grant Mr. Ramat a stock option exercisable for 100,000 shares of common stock of Neurotrope (the “Financing Option”) in the event the Company successfully completes a financing pursuant to which it raises at least ten million dollars ($10,000,000). The Financing Option will be issued to Mr. Ramat on the date of the closing of the applicable financing (assuming Mr. Ramat’s continued service as the President and Chief Executive Officer of Neurotrope as of such date), will be fully vested as of the date of grant, and will have an exercise price per share equal to the price per share paid by investors for securities of Neurotrope in the applicable financing.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies: (Policies)	3 Months Ended
	Mar. 31, 2015
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates:
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Reclassification, Policy [Policy Text Block]	Reclassifications:
	Certain reclassifications have been made to the 2014 financial statements to conform to the consolidated 2015 financial statement presentation. These reclassifications had no effect on net loss or cash flows as previously reported.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents:
	The Company considers all highly liquid temporary cash investments with an original maturity of three months or less when purchased to be cash equivalents. At March 31, 2015, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment:
	Property and equipment is capitalized and depreciated on a straight line basis over the useful life of the asset, which is deemed to be between three and ten years. Property and equipment consist of the following:
		March 31,		December 31,
		2015		2014
	Property and equipment	$	57,987	$	54,943
	Accumulated depreciation	$	-2,762	$	-1,325
	Property and equipment, net	$	55,225	$	53,618
	Depreciation expense for the three months ended March 31, 2015 and 2014 was $1,436 and $0, respectively.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs:
	All research and development costs, including costs to maintain or expand the Company’s patent portfolio that do not meet the criteria for capitalization are expensed when incurred. FASB ASC Topic 730 requires companies involved in research and development activities to capitalize non-refundable advance payments for such services pursuant to contractual arrangements because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at March 31, 2015 and December 31, 2014.
Income Tax, Policy [Policy Text Block]	Income Taxes:
	Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes. Deferred taxes are recognized for differences between the bases of assets and liabilities for financial statement and income tax purposes and the tax effects of net operating loss and other carryforwards. The deferred tax assets and liabilities represent the future tax consequences of those differences and carryforwards, which will either be taxable or deductible when the related assets, liabilities or carryforwards are recovered or settled. Deferred tax assets are reduced by a valuation allowance when, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized.
	The Company applies the provisions of FASB ASC 740-10, Accounting for Uncertain Tax Positions, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The standard also provides guidance on de-recognition, classification, interest and penalties, and accounting in interim periods, disclosure and transitions.
	The Company has concluded that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions is from October 31, 2012 (inception) through March 31, 2015.
	In the event the Company was to receive an assessment for interest and/or penalties, it will be classified in the financial statements as selling, general and administrative expense when assessed.
Income Tax Uncertainties, Policy [Policy Text Block]	Risks and Uncertainties:
	The Company operates in an industry that is subject to rapid technological change, intense competition and significant government regulation. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risk. Such factors include, but are not necessarily limited to, the results of clinical testing and trial activities, the ability to obtain regulatory approval, the ability to obtain favorable licensing, manufacturing or other agreements for its product candidates and the ability to raise capital to achieve strategic objectives.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock Compensation:
	The Company accounts for stock-based awards to employees in accordance with applicable accounting principles, which requires compensation expense related to share-based transactions, including employee stock options, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. For all employee stock options, we recognize expense over the employee’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the expected stock price volatility, expected term, and forfeiture rate. Any changes in these highly subjective assumptions significantly impact stock-based compensation expense.
	Options awarded to purchase shares of common stock issued to non-employees in exchange for services are accounted for as variable awards in accordance with applicable accounting principles. Such options are valued using the Black-Scholes option pricing model.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies: (Tables)	3 Months Ended
	Mar. 31, 2015
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment is capitalized and depreciated on a straight line basis over the useful life of the asset, which is deemed to be between three and ten years. Property and equipment consist of the following:
		March 31,		December 31,
		2015		2014
	Property and equipment	$	57,987	$	54,943
	Accumulated depreciation	$	-2,762	$	-1,325
	Property and equipment, net	$	55,225	$	53,618

Stock_Options_Tables

Stock Options: (Tables)	3 Months Ended
	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the Company’s stock option activity for the three months ending March 31, 2015 is as follows:
		Options	Weighted-Average
		Outstanding	Exercise Price
	Outstanding at January 1, 2015	7,769,202	$	1.4
	Options granted	70,000	$	1.17
	Options forfeited	-51,250	$	-1.52
	Options exercised	0		0
	Outstanding at March 31, 2015	7,787,952	$	1.39
	Options exercisable March 31, 2015	4,738,294	$	1.49

Common_and_Preferred_Stock_Res1

Common and Preferred Stock Reserved for Future Issuances: (Tables)	3 Months Ended
	Mar. 31, 2015
Common And Preferred Stock Reserved For Future Issuances [Abstract]
Schedule of Guarantor Obligations [Table Text Block]	Common stock reserved for future issuances consisted of the following at March 31, 2015:
		Common Stock
		Reserved
	Common stock warrants outstanding		1,375,432
	Common stock options outstanding		7,787,952
	Conversion of Series A Preferred Stock		18,757,394
	Total		27,920,778

Summary_of_Significant_Account3

Summary of Significant Accounting Policies: (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment	$57,987	$54,943
Accumulated depreciation	-2,762	-1,325
Property and equipment, net	$55,225	$53,618

Summary_of_Significant_Account4

Summary of Significant Accounting Policies: (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Summary Of Significant Accounting Policies [Line Items]
Depreciation, Depletion and Amortization	$1,436	$0
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	3 years

Contractual_Commitments_Detail

Contractual Commitments: (Details Textual) (USD $)

0 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

2 Months Ended

Sep. 04, 2014

Mar. 31, 2015

Sep. 12, 2014

Jul. 16, 2014

Feb. 28, 2013

Jul. 23, 2014

Jun. 30, 2014

Jan. 31, 2014

Oct. 30, 2013

Nov. 01, 2014

Dec. 31, 2014

Oct. 09, 2014

Feb. 28, 2013

acre

Contractual Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

8 years 7 months 6 days

Area of Land

4,000

Description of Lessor Leasing Arrangements, Operating Leases

The lease commenced September 1, 2014 and expires December 1, 2017 and has two (2) one-year renewal options.

Accrued Rent

$88,000

Ramat [Member]

Contractual Commitments And Contingencies [Line Items]

Consulting Fees

400,000

20,000

50,000

Service Cost Paid Under Installment

4,167

Stock Option Entitled To Related Party

300,000

Stock Option Entitled To Related Party Purchase Price Per Share

$1

1

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

20.00%

Targeted Bonus Percentage Of Base Consulting Fees

50.00%

Consulting Fees Total

50,000

Freiman [Member]

Contractual Commitments And Contingencies [Line Items]

Consulting Fees

20,000

Freiman And Ramat [Member]

Contractual Commitments And Contingencies [Line Items]

Consulting Fees

20,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price

$0.60

Consulting Fees Reduced Amount

10,000

Share-based Compensation Arrangement by Share-based Payment Award, Description

options to purchase 400,000 shares of the Company’s common stock for their roles as directors, Co-Chairmen of the Board and Co-Chief Executive Officers. Options to purchase 200,000 shares have an exercise price of $1.11 per share, or 110% of the Company’s last trading price on July 23, 2014 and were fully vested upon grant. Options to purchase the remaining 200,000 shares have an exercise price of $2.22 per share based upon two times the exercise price of $1.11 per share and vest on a daily basis up to 25% per year through July 23, 2018

Executive Director - Pharmacology [Member]

Contractual Commitments And Contingencies [Line Items]

Annual Salary Providing Under Agreement

180,000

Targeted Bonus Percentage Of Base Salary

25.00%

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

50,000

Employment Contracts [Member] | Vice President - Commercial Operations [Member]

Contractual Commitments And Contingencies [Line Items]

Annual Salary Providing Under Agreement

210,000

Targeted Bonus Percentage Of Base Salary

35.00%

Employment Contracts [Member] | Chief Medical Officer and Vice President [Member]

Contractual Commitments And Contingencies [Line Items]

Annual Salary Providing Under Agreement

210,000

Employment Contracts [Member] | Chief Financial Officer [Member]

Contractual Commitments And Contingencies [Line Items]

Annual Salary Providing Under Agreement

240,000

Increasing Decrease In Annual Salary

275,000

Employment Contracts [Member] | Chief Financial Officer [Member] | Scenario, Forecast [Member]

Contractual Commitments And Contingencies [Line Items]

Targeted Bonus Percentage Of Base Salary

50.00%

Employment Contracts [Member] | Executive Vice President [Member]

Contractual Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

20.00%

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

5 years

Salaries, Wages and Officers' Compensation

325,000

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

250,000

Deferred Compensation Arrangement with Individual, Exercise Price

$0.71

Deferred Compensation Arrangement with Individual, Maximum Contractual Term

1 year

Employment Contracts [Member] | Executive Vice President [Member] | Deferred Bonus [Member]

Contractual Commitments And Contingencies [Line Items]

Monthly Signing Bonus

8,507

Salaries, Wages and Officers' Compensation

102,083

Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage

50.00%

Employment Contracts [Member] | Qualifed Stock Option [Member] | Vice President - Commercial Operations [Member]

Contractual Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

5 years

Share Based Compensation Arrangement By Share Based Payment Award Options Vested Percentage

20.00%

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

100,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

10 years

Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price

$1.76

Employment Contracts [Member] | Qualifed Stock Option [Member] | Chief Medical Officer and Vice President [Member]

Contractual Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

25.00%

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

4 years

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

125,000

31,250

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

10 years

Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price

$1.76

Severance Costs

217,000

Employment Contracts [Member] | Qualifed Stock Option [Member] | Chief Financial Officer [Member]

Contractual Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

25.00%

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

4 years

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

650,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

10 years

Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price

$1

Non-Qualified Stock Options [Member] | Ramat [Member]

Contractual Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

250,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

10 years

Non-Qualified Stock Options [Member] | Freiman [Member]

Contractual Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

50,000

Separation Agreement [Member] | Former President [Member]

Contractual Commitments And Contingencies [Line Items]

Reimbursement Of Attorney Fee

17,000

Deferred Compensation Arrangement with Individual, Compensation Expense

2,684

Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount

233,000

Accrued Vacation

25,478

Supplemental Unemployment Benefits, Continuation of Health Care

2,974

Deferred Compensation Arrangement with Individual, Distributions Paid

$282,000

Series A Preferred Stock [Member] | Ramat [Member]

Contractual Commitments And Contingencies [Line Items]

Stock Option Entitled To Related Party

1,000,000

Collaborative_Agreements_Detai

Collaborative Agreements: (Details Textual) (USD $)	0 Months Ended	3 Months Ended	12 Months Ended
	15-May-14	Mar. 31, 2015	Dec. 31, 2014
Contract Research Organization [Member]
Collaborative Agreements [Line Items]
Commitment To Pay Fees	$715,159
Reduction Of Commitment Fees		657,238
Payments for Fees		687,112
Accounts Payable		377,225	417,877
Worldwide Clinical Trials [Member]
Collaborative Agreements [Line Items]
Professional Fees		300,000
Stanford Agreement [Member]
Collaborative Agreements [Line Items]
License Initiation Fee			60,850
Annual License Maintenance Fee			10,000
Milestone Payments Upon Achievement Of Certain Product			3,700,000
Payment For License Agreement Fees			48,564
Mount Sinai Agreement [Member]
Collaborative Agreements [Line Items]
License Initiation Fee		25,000
Annual License Maintenance Fee		10,000
Milestone Payments Upon Achievement Of Certain Product		3,500,000
Accounts payable and accrued expenses		12,000
Payment For License Agreement Fees			$11,458

Related_Party_Transactions_and1

Related Party Transactions and Licensing / Research Agreements: (Details Textual) (USD $)	3 Months Ended		12 Months Ended	1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Sep. 30, 2015	Feb. 28, 2013	Dec. 31, 2014	Feb. 28, 2015
Related Party Transaction [Line Items]
Technology Services Costs	$600,000
Research and Development Expense, Total	492,657	0
Due to Related Parties, Current	0				200,000
BRNI License Agreement [Member]
Related Party Transaction [Line Items]
Accounts Payable, Other, Current						200,000
Due to Related Parties, Current						600,000
Repayments of Related Party Debt	20,000
Proceeds from Related Party Debt	150,000
Scenario, Forecast [Member]
Related Party Transaction [Line Items]
Research and Development Expense, Total	1,000,000
Subsequent Event [Member] | BRNI License Agreement [Member]
Related Party Transaction [Line Items]
Payments for Fees			2,400,000
Fixed Research Fee [Member]
Related Party Transaction [Line Items]
Research and Development Expense, Total	1,000,000
Services Reimbursement [Member]
Related Party Transaction [Line Items]
Royalties Percentage	5.00%
Services Reimbursement [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Royalties Percentage	2.00%
Services Reimbursement [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Royalties Percentage	5.00%
Statement Of Work Agreement [Member]
Related Party Transaction [Line Items]
Payments for Fees	200,000	400,000
Series A Preferred Stock [Member] | Technology License And Services Agreement [Member]
Related Party Transaction [Line Items]
Proceeds from Issuance of Preferred Stock and Preference Stock				8,000,000
Series B Preferred Stock [Member] | Fixed Research Fee [Member]
Related Party Transaction [Line Items]
Proceeds from Issuance of Preferred Stock and Preference Stock	$25,000,000
Director [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage	33.60%

Income_Taxes_Details_Textual

Income Taxes: (Details Textual) (USD $)	29 Months Ended
	Mar. 31, 2015
Income Tax Expenses Benefit [Line Items]
Operating Income (Loss)	$15,990,210
Deferred Tax Assets, Net	$250,000

Common_Stock_Details_Textual

Common Stock: (Details Textual) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Conversion of Stock, Shares Converted	2,605,606	1,637,000
Convertible Preferred Stock, Shares Issued upon Conversion	2,605,606	1,637,000
Neurotrope Inc. [Member] | Common Stock [Member]
Class of Stock [Line Items]
Warrants Exercisable	236,340	613,228
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	236,340	613,228
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.01	0.01

Stock_Options_Details

Stock Options: (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding	7,769,202
Options granted	70,000
Options forfeited	-51,250
Options exercised	0
Outstanding	7,787,952
Options exercisable	4,738,294
Weighted-Average Exercise Price, Outstanding	$1.40
Weighted-Average Exercise Price, Options granted	$1.17
Weighted - Average Exercise Price, Options forfeited	($1.52)
Weighted-Average Exercise Price, Options exercised	$0
Weighted-Average Exercise Price, Outstanding	$1.39
Weighted-Average Exercise Price, Options exercisable	$1.49

Stock_Options_Details_Textual

Stock Options: (Details Textual) (USD $)	3 Months Ended		1 Months Ended	0 Months Ended	1 Months Ended	0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jul. 23, 2014	Sep. 12, 2014	Jan. 23, 2014	Jul. 16, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$1.49
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	91.85%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.98%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$1.02
Employee Benefits and Share-based Compensation	$61,822	$170,920
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	8 years 7 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	8 years 8 months 12 days
Non-Qualified Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period			3,000,000
Director [Member] | Non-Qualified Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period				300,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price				$0.60
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Period				5 years
Three Employee [Member] | Plan 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period					300,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price					$1.76
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights					125,000 of these options vest 25% per year, with accelerated vesting of 25% upon a termination without cause or for good reason, with the remaining 175,000 vesting 20% per year.
One Employee [Member] | Plan 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	30,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$2.30
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Chief Executive Officer [Member] | Non-Qualified Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period				250,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price				$0.60
Chairman [Member] | Non-Qualified Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period				50,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price				$0.60
Equity Incentive Plan 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	7,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	5,154,404
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Share-based Compensation Arrangement by Share-based Payment Award, Description			Also, on July 23, 2014, the Board granted non-qualified stock options to three directors, each in the amount of 100,000 shares of common stock; 50,000 of which have an exercise price equal to $1.11, which vested on the date of the grant hereof; and 50,000 of which have an exercise price equal to two times the value of the exercise price of the first 50,000 options, or $2.22 which vest daily over four (4) years (assuming continued service on behalf of the Company), up to 25% per year, until the grant is fully vested on July 23, 2018.
Equity Incentive Plan 2013 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period			10,000,000
Equity Incentive Plan 2013 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period			3,000,000
Equity Incentive Plan 2013 [Member] | Founding Stock Holder [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	3,500,000
Equity Incentive Plan 2013 [Member] | Consultant One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	54,404
Equity Incentive Plan 2013 [Member] | Founding Stock Holder and Consultant One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$1.75
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	100.00%
Equity Incentive Plan 2013 [Member] | Consultant Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	250,000
Equity Incentive Plan 2013 [Member] | Consultant Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	300,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$1
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Period	4 years
Equity Incentive Plan 2013 [Member] | One Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period				20,000		50,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price				$0.60		$1.24
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				20.00%		20.00%
Equity Incentive Plan 2013 [Member] | Four Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	1,050,000
Equity Incentive Plan 2013 [Member] | Four Directors And Consultant Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$1
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Period	5 years

Common_and_Preferred_Stock_Res2

Common and Preferred Stock Reserved for Future Issuances: (Details)	Mar. 31, 2015
Class of Stock [Line Items]
Common Stock Reserved	27,920,778
Common Stock Warrant Outstanding [Member]
Class of Stock [Line Items]
Common Stock Reserved	1,375,432
Common Stock Option Outstanding [Member]
Class of Stock [Line Items]
Common Stock Reserved	7,787,952
Conversion of Series A Preferred Stock [Member]
Class of Stock [Line Items]
Common Stock Reserved	18,757,394

Common_and_Preferred_Stock_Res3

Common and Preferred Stock Reserved for Future Issuances: (Details Textual)	3 Months Ended	12 Months Ended	0 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Feb. 09, 2015
Conversion of Stock, Shares Converted	2,605,606	1,637,000
Warrant Holder [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1,325,000
Series A Preferred Stock [Member] | Warrant Holder [Member]
Conversion of Stock, Shares Converted			1,325,000

Subsequent_Events_Details_Text

Subsequent Events: (Details Textual) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Subsequent Event [Line Items]
Conversion of Stock, Shares Converted	2,605,606	1,637,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	4,738,294
Investor [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities	614,500
Series A Preferred Stock [Member] | Warrant Holder [Member]
Subsequent Event [Line Items]
Conversion of Stock, Shares Converted	614,500
Financing Option [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	100,000
Stock Issued During Period, Value, Acquisitions	10,000,000